Peptides and proteins used to enhance gold nanoparticle delivery to the brain: Preclinical approaches

Carolina Velasco-Aguirre, Francisco Morales, Eduardo Gallardo-Toledo, Simon Guerrero, Ernest Giralt, Eyleen Araya, Marcelo J. Kogan

Resultado de la investigación: Review article

43 Citas (Scopus)

Resumen

An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.

Idioma originalEnglish
Páginas (desde-hasta)4919-4936
Número de páginas18
PublicaciónInternational Journal of Nanomedicine
Volumen10
DOI
EstadoPublished - 10 ago 2015

Huella dactilar

Gold
Nanoparticles
Peptides
Brain
Brain Diseases
Proteins
Nanomedicine
Neurology
Intranasal Administration
Central Nervous System Diseases
Medical nanotechnology
Central Nervous System
Clinical Trials
Therapeutics
Tumors
Research
Physical properties
Neoplasms

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Citar esto

Velasco-Aguirre, C., Morales, F., Gallardo-Toledo, E., Guerrero, S., Giralt, E., Araya, E., & Kogan, M. J. (2015). Peptides and proteins used to enhance gold nanoparticle delivery to the brain: Preclinical approaches. International Journal of Nanomedicine, 10, 4919-4936. https://doi.org/10.2147/IJN.S82310
Velasco-Aguirre, Carolina ; Morales, Francisco ; Gallardo-Toledo, Eduardo ; Guerrero, Simon ; Giralt, Ernest ; Araya, Eyleen ; Kogan, Marcelo J. / Peptides and proteins used to enhance gold nanoparticle delivery to the brain : Preclinical approaches. En: International Journal of Nanomedicine. 2015 ; Vol. 10. pp. 4919-4936.
@article{6d083850a60646ab9d0af397ec231acb,
title = "Peptides and proteins used to enhance gold nanoparticle delivery to the brain: Preclinical approaches",
abstract = "An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.",
keywords = "Biodistribution, Blood–brain barrier, Central nervous system, Drug delivery, EPR effect, Transcytosis",
author = "Carolina Velasco-Aguirre and Francisco Morales and Eduardo Gallardo-Toledo and Simon Guerrero and Ernest Giralt and Eyleen Araya and Kogan, {Marcelo J.}",
year = "2015",
month = "8",
day = "10",
doi = "10.2147/IJN.S82310",
language = "English",
volume = "10",
pages = "4919--4936",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

Velasco-Aguirre, C, Morales, F, Gallardo-Toledo, E, Guerrero, S, Giralt, E, Araya, E & Kogan, MJ 2015, 'Peptides and proteins used to enhance gold nanoparticle delivery to the brain: Preclinical approaches', International Journal of Nanomedicine, vol. 10, pp. 4919-4936. https://doi.org/10.2147/IJN.S82310

Peptides and proteins used to enhance gold nanoparticle delivery to the brain : Preclinical approaches. / Velasco-Aguirre, Carolina; Morales, Francisco; Gallardo-Toledo, Eduardo; Guerrero, Simon; Giralt, Ernest; Araya, Eyleen; Kogan, Marcelo J.

En: International Journal of Nanomedicine, Vol. 10, 10.08.2015, p. 4919-4936.

Resultado de la investigación: Review article

TY - JOUR

T1 - Peptides and proteins used to enhance gold nanoparticle delivery to the brain

T2 - Preclinical approaches

AU - Velasco-Aguirre, Carolina

AU - Morales, Francisco

AU - Gallardo-Toledo, Eduardo

AU - Guerrero, Simon

AU - Giralt, Ernest

AU - Araya, Eyleen

AU - Kogan, Marcelo J.

PY - 2015/8/10

Y1 - 2015/8/10

N2 - An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.

AB - An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.

KW - Biodistribution

KW - Blood–brain barrier

KW - Central nervous system

KW - Drug delivery

KW - EPR effect

KW - Transcytosis

UR - http://www.scopus.com/inward/record.url?scp=84981717459&partnerID=8YFLogxK

U2 - 10.2147/IJN.S82310

DO - 10.2147/IJN.S82310

M3 - Review article

C2 - 26300639

AN - SCOPUS:84981717459

VL - 10

SP - 4919

EP - 4936

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -